

**Supplementary Table 5: Studies reporting an association between EGFR mutations and the new IASLC/ATS/ERS 2011 adenocarcinoma histologic subtyping**

Author, year	Country	Number tested for EGFR	Predominant TNM stage	Sample tested for HPE subtyping	Type of analysis	Histologic subtype with increased prevalence (%)	Histologic subtype with decreased prevalence (%)	P
East Asians								
Shim <i>et al.</i> , 2011 <sup>[1]</sup>	Korea	107	Stages I-III A	Resected specimen	Univariate	Micropapillary (83.3)	Solid (28.6)	<0.05
Sun <i>et al.</i> , 2012 <sup>[2]</sup>	Korea	382	Stages I-IV	Resected specimens	Univariate	Papillary (70)	IMA (33.3)	0.06
Kim <i>et al.</i> , 2014 <sup>[3]</sup>	Korea	359	Stages I-IV	Small biopsies	Univariate	Acinar (56.6)	Solid (38.9)	<0.001
Lee <i>et al.</i> , 2014 <sup>[20]</sup>	Korea	153	Stages I-III A	Resected specimens	Univariate	Papillary (77.8)	Solid (16.7)	<0.001
Yoshizawa, <i>et al.</i> , 2013 <sup>[5]</sup>	Japan	167	Stages I-III A	Resected specimen	Univariate	Lepidic (61.1)	IMA (0)	<0.001
Tsuta <i>et al.</i> , 2013 <sup>[4]</sup>	Japan	904	Stages I-III	Resected specimens	Univariate	Lepidic (74.4)	Solid (14.3)	<0.001
Yanagawa <i>et al.</i> , 2014 <sup>[6]</sup>	Japan	241	Stages I-III B	Resected specimen	Descriptive only	Papillary (56)	Solid (15.8)	NA
						Lepidic (77)	IMA (0)	
						Acinar (49)	Solid (28)	
Nakamura <i>et al.</i> , 2014 <sup>[7]</sup>	Japan	320	Stages I-II	Resected specimen	Univariate	Papillary (50)	Solid (17.4)	NS
Zhang <i>et al.</i> , 2012 <sup>[8]</sup>	China	349	Stages I-IV	Resected specimen	Multivariate	Acinar (43.8)	-	0.005
Li <i>et al.</i> , 2013 <sup>[9]</sup>	China	230	Stages I-III A	Resected specimen	Univariate	Papillary (48.4)	IMA (0)	<0.05
						Acinar (83.1)	Solid (22.6)	
						Micropapillary (84.6)	IMA (0)	
						Lepidic (88.9)	Solid (22.6)	
Song <i>et al.</i> , 2013 <sup>[10]</sup>	China	161	Stages I-III	Resected specimen	Univariate	Papillary (57.6)	Solid	<0.05
Hu <i>et al.</i> , 2014 <sup>[11]</sup>	China	981	Stages I-III A	Resected specimen	Multivariate	Lepidic	Solid (37)	<0.001
Chen <i>et al.</i> , 2014 <sup>[12]</sup>	China	206	Stages I-IV	Resected specimen	Univariate	Micropapillary	IMA (14)	<0.05
						Lepidic (68.8)	Solid (22.5)	
						Papillary (70.7)	IMA (25)	
						Acinar (69.5)	IMA (25)	
Liu <i>et al.</i> , 2014 <sup>[13]</sup>	China	139	Stages I-III	Resected specimen	Univariate	Papillary (66.7)	Solid (25)	0.038
							IMA (27.3)	
Caucasians								
Russell <i>et al.</i> , 2013 <sup>[14]</sup>	Australia	69	Stage III (N2 disease)	Resected specimen	Univariate	Acinar (44)	Solid (4.2)	0.009
Girard <i>et al.</i> , 2012 <sup>[15]</sup>	USA	2392	Stages I-IV	Resected specimens and small biopsies	Multivariate	Micropapillary (38)	-	<0.001
Villa <i>et al.</i> , 2014 <sup>[16]</sup>	USA	200	Stages I-III	Resected specimens	Univariate	Papillary (46.4)	Solid (7)	<0.001
Kadota <i>et al.</i> , 2014 <sup>[17]</sup>	USA	864	Stages I-III	Resected specimens	Univariate	Lepidic (32.2)	Solid (4)	<0.05
						Lepidic (44)	IMA (0)	
						Lepidic (28)	IMA (0)	

Contd...

### Supplementary Table 5: Contd...

Author, year	Country	Number tested for EGFR	Predominant TNM stage	Sample tested for HPE subtyping	Type of analysis	Histologic subtype with increased prevalence (%)	Histologic subtype with decreased prevalence (%)	P
Mansuet-Lupo <i>et al.</i> , 2014 <sup>[18]</sup>	France	397	Stages I-III	Resected specimens	Multivariate	Lepidic (18.2) Acinar (11.4)	Solid (2.8)	0.003
Campos-Parra <i>et al.</i> , 2014 <sup>[19]</sup>	Mexico	257	Stages IIIB-IV	Small biopsies	Univariate			NS

NA: Not available, NS: Nonsignificant, IMA: Invasive Mucinous Adenocarcinoma, EGFR: Epidermal growth factor receptor, IASLC: International Association for the Study of Lung Cancer, ATS: American Thoracic Society, ERS: European Respiratory Society, HPE: Histopathology examination, TNM: Tumor node metastasis

### SUPPLEMENTARY REFERENCES

- Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. *Arch Pathol Lab Med* 2011;135:1329-34.
- Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, *et al.* High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: Correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. *J Thorac Oncol* 2012;7:323-30.
- Kim HJ, Choi EY, Jin HJ, Shin KC. Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies. *Anticancer Res* 2014;34:3189-95.
- Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, *et al.* The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. *Lung Cancer* 2013;81:371-6.
- Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, *et al.* Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. *J Thorac Oncol* 2013;8:52-61.
- Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. *Ann Thorac Surg* 2014;98:453-8.
- Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, *et al.* Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. *Clin Lung Cancer* 2015;16:209-15.
- Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, *et al.* Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. *Clin Cancer Res* 2012;18:1947-53.
- Li H, Pan Y, Li Y, Li C, Wang R, Hu H, *et al.* Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. *Lung Cancer* 2013;79:8-13.
- Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. *Med Oncol* 2013;30:645.
- Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, *et al.* Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. *Onco Targets Ther* 2014;7:1423-37.
- Chen Z, Liu X, Zhao J, Yang H, Teng X. Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. *Int J Clin Exp Pathol* 2014;7:8039-45.
- Liu J, Li XY, Zhao YQ, Liu RQ, Zhang JB, Ma J, *et al.* Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TTF-1/SP-A expressions and EGFR mutations. *Pathol Res Pract* 2014;210:176-81.
- Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, *et al.* Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. *J Thorac Oncol* 2013;8:461-8.
- Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, *et al.* Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. *Eur Respir J* 2012;39:366-72.
- Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, *et al.* Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. *Arch Pathol Lab Med* 2014;138:1353-7.
- Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, *et al.* Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: Invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol* 2014;38:1118-27.
- Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, *et al.* The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: The experience of a French cohort. *Chest* 2014;146:633-43.
- Campos-Parra AD, Avilés A, Contreras-Reyes S, Rojas-Marín CE, Sánchez-Reyes R, Borbolla-Escoboza RJ, *et al.* Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. *Eur Respir J* 2014;43:1439-47.
- Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, *et al.* Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. *Radiology* 2013;268:254-64.